Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1236 · 3 trials · 2 indications
Number of patients who had an Adverse Event
Ratio reflects Sputum Tumor Necrosis Factor alpha (TNF alpha) at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).
Ratio reflects Sputum Total Cells at week 6 value divide by baseline value. Baseline is geometric mean of Visit 2 (last value during run-in) and Visit 3 (Randomization).
Ratio reflects Total Urine Desmosine at week 6 value divide by baseline value. Baseline is visit 3(Randomization) value.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| AZD1236 | EXPERIMENTAL | oral tablet, 75 mg, twice daily during 6 weeks |
| Placebo | PLACEBO_COMPARATOR | Dosing to match AZD1236 |
| Active | EXPERIMENTAL | AZD1236 tablet |
| Relative bioavailability | OTHER | AZD1236 Oral suspension |
| Relative bioavailability tablet | OTHER | AZD1236 tablet |
| Name | Type | Description |
|---|---|---|
| AZD1236 | DRUG | oral tablet, 75 mg, twice daily during 6 weeks |
| Placebo | DRUG | Dosing to match AZD1236 |
Inclusion Criteria: * Diagnosis of COPD for 1 month * Men or postmenopausal women * Spirometry values indicating reduced lung function * Smoking history equivalent to using 20 cigarettes a day for 10 years Exclusion Criteria: * Any current respiratory tract disorders other than COPD * Requirement...
AZD1236 is an investigational small molecule being studied for chronic obstructive pulmonary disease (COPD). It has been evaluated in Phase 2 clinical trials in COPD patients and in a Phase 1 study in healthy volunteers. The drug is being developed by AstraZeneca PLC (AZN).
AZD1236 is a small molecule being developed by AstraZeneca for respiratory disease. Its specific molecular target has not been disclosed in the available clinical trial information. The drug has been studied in Phase 2 trials for chronic obstructive pulmonary disease (COPD).
AZD1236 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca has sponsored clinical trials of AZD1236 in chronic obstructive pulmonary disease (COPD) and in healthy volunteers.
AZD1236 is in Phase 2 clinical development for chronic obstructive pulmonary disease (COPD). Two Phase 2 trials in COPD patients have been completed, along with a Phase 1 study in healthy volunteers. AZD1236 is investigational and has not been approved by regulatory authorities.
AZD1236 has been studied in three completed clinical trials. NCT00758459 was a Phase 2 safety and tolerability study in 74 COPD patients. NCT00758706 was a Phase 2a biomarker study in 55 COPD patients. NCT00767052 was a Phase 1 pharmacokinetic study in 48 healthy male volunteers in Japan.
AZD1236 is the code name used for this investigational compound in clinical trials. No alternative brand names or other designations have been reported in the clinical trial information. The drug is being studied under the name AZD1236 by AstraZeneca.